Search Results

Biotech Bay

Trianni Secures an EU Patent on the Trianni Mouse® Antibody Discovery Platform

Trianni, Inc. (“TRIANNI”) announced today that the European Patent Office granted patent EP 2597945 for TRIANNI’s leading technology, The Trianni Mouse®. The Trianni Mouse is a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies.

July 22, 2020

·

1 min read

Biotech Bay

Trianni, Inc. Announces License Agreement with Nkarta, Inc. for the Trianni Mouse®

Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement with Nkarta, Inc. (“NKARTA”) for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support NKARTA’s antibody-based therapeutic discovery programs.

March 10, 2020

·

1 min read

Biotech Bay

Trianni, Inc. and Mablytics, Inc. Announce License Agreement for the Trianni Mouse®

Trianni, Inc. (“TRIANNI”) and Mablytics, Inc. (“MABLYTICS”) jointly announced today that they have entered into a license agreement for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support MABLYTICS’ antibody-based therapeutic discovery programs.

February 4, 2020

·

1 min read

Business

Trianni, Inc. Announces License Agreement with Artizan Biosciences, Inc. for the Trianni Mouse®

Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement with Artizan Biosciences, Inc. (“Artizan”) for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support Artizan’s antibody-based therapeutic discovery programs.

February 25, 2020

·

1 min read

AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology.

January 19, 2021

·

4 min read

Business

Trianni, Inc. Announces License Agreement with Zymeworks Inc. for use of the Trianni Mouse®

Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement with Zymeworks Inc. (“ZYMEWORKS”) for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support ZYMEWORKS’ therapeutic discovery programs.

September 10, 2019

·

1 min read

Deals

AbCellera Expands Technology Stack with Acquisition of Trianni for $90 Million

AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease, today announced it has acquired Trianni, Inc. in an all-cash transaction valued at US$90 million.

November 18, 2020

·

3 min read

Biotech Bay

Trianni and Zoetis Announce Agreement to Develop a Transgenic Antibody Discovery Platform for Use in Animal Health

Trianni, Inc. and Zoetis announced a collaboration for the development of transgenic monoclonal antibody platforms for the discovery of new veterinary treatments.

July 7, 2020

·

3 min read

Biotech Bay

Trianni, Inc. Announces Issuance of Patent in Japan

Trianni, Inc. (“TRIANNI”) announced today that the Japan Patent Office granted the patent for TRIANNI’s leading technology, The Trianni Mouse

February 28, 2019

·

1 min read

Biotech Bay

New Patent Issued to Trianni: Antibody Discovery Platform Optimized for Man’s Best Friend -- the Dog

Trianni, Inc. announced that its patent on the generation of its “dog mouse” has been issued in the U.S.

May 26, 2020

·

1 min read